+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials



Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials



Ophthalmology 123(8): 1751-1761



To describe outcomes 5 years after initiating treatment with bevacizumab or ranibizumab for neovascular age-related macular degeneration (AMD). Cohort study. Patients enrolled in the Comparison of AMD Treatments Trials. Patients were assigned randomly to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. After 2 years, patients were released from the clinical trial protocol. At 5 years, patients were recalled for examination. Visual acuity (VA) and morphologic retinal features. Visual acuity was obtained for 647 of 914 (71%) living patients with average follow-up of 5.5 years. The mean number of examinations for AMD care after the clinical trial ended was 25.3, and the mean number of treatments was 15.4. Most patients (60%) were treated 1 time or more with a drug other than their assigned drug. At the 5-year visit, 50% of eyes had VA of 20/40 or better and 20% had VA of 20/200 or worse. Mean change in VA was -3 letters from baseline and -11 letters from 2 years. Among 467 eyes with fluorescein angiography, mean total lesion area was 12.9 mm(2), a mean of 4.8 mm(2) larger than at 2 years. Geographic atrophy was present in 213 of 515 (41%) gradable eyes and was subfoveal in 85 eyes (17%). Among 555 eyes with spectral-domain optical coherence tomography, 83% had fluid (61% intraretinal, 38% subretinal, and 36% sub-retinal pigment epithelium). Mean foveal total thickness was 278 μm, a decrease of 182 μm from baseline and 20 μm from 2 years. The retina was abnormally thin (<120 μm) in 36% of eyes. Between 2 and 5 years, the group originally assigned to ranibizumab for 2 years lost more VA than the bevacizumab group (-4 letters; P = 0.008). Otherwise, there were no statistically significant differences in VA or morphologic outcomes between drug or regimen groups. Vision gains during the first 2 years were not maintained at 5 years. However, 50% of eyes had VA of 20/40 or better, confirming anti-vascular endothelial growth factor therapy as a major long-term therapeutic advance for neovascular AMD.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057883634

Download citation: RISBibTeXText

PMID: 27156698

DOI: 10.1016/j.ophtha.2016.03.045


Related references

Anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration: Comparison of Age-related Macular Degeneration Treatments Trials 5 year outcomes and implication for clinical practice. Clinical and Experimental Ophthalmology 45(4): 333-335, 2017

Predictors of One-Year Visual Outcomes After Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. Retina 38(8): 1492-1499, 2018

Five-year outcomes of a personalized pro re nata treatment regimen with anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Acta Ophthalmologica 97(1): E131, 2019

An 8-year follow-up of anti-vascular endothelial growth factor treatment with a treat-and-extend modality for neovascular age-related macular degeneration. Acta Ophthalmologica 95(8): 796-802, 2017

Effect of Intraocular Pressure-Lowering Medications on Neovascular Age-Related Macular Degeneration Treatment Outcomes in the Comparison of Age-Related Macular Degeneration Treatment Trials. Retina 39(4): 636-647, 2019

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. Bmc Ophthalmology 18(1): 130, 2018

MACULAR ATROPHY INCIDENCE IN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR-TREATED NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Risk Factor Evaluation for Individualized Treatment Need of Ranibizumab or Aflibercept According to an Observe-and-Plan Regimen. Retina 39(5): 906-917, 2019

Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Choroidal Neovascularization in Fellow Eyes of Previously Treated Patients With Neovascular Age-Related Macular Degeneration. JAMA Ophthalmology 136(7): 820-823, 2018

Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis. Medicine 96(50): E9345, 2017

EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy. Retina 35(8): 1540-1546, 2015

Outcomes of cataract surgery in patients with neovascular age-related macular degeneration in the era of anti-vascular endothelial growth factor therapy. Journal of Cataract and Refractive Surgery 38(4): 677-682, 2012

Anti-Vascular Endothelial Growth Factor Intravitreal Therapy and Macular Ganglion Cell Layer Thickness in Patients with Neovascular Age-Related Macular Degeneration. Current Eye Research 44(9): 1000-1005, 2019

Disparities in access to anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration. Clinical and Experimental Ophthalmology 45(2): 143-151, 2017

ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Outcomes in Eyes With Poor Initial Vision. Retina 35(10): 1957-1963, 2015

Real-world Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration in the United States. Ophthalmology. Retina 2(7): 645-653, 2018